Document is current
Any future updates will be listed below
-
Authors
Cardenas, Matias https://orcid.org/0000-0001-8247-3669
Compton, Sasha
Caceres, C. Joaquin https://orcid.org/0000-0001-8508-6592
García-Sastre, Adolfo https://orcid.org/0000-0002-6551-1827
Perez, Daniel R. https://orcid.org/0000-0002-6569-5689
Rajao, Daniela S. https://orcid.org/0000-0002-0772-0065
-
Funding
Funding for this research was provided by:
United States Department of Agriculture | National Institute of Food and Agriculture (2020-67015-31563)
National Pork Board (21-085)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93021C00014)
- License Information
-
More Information
Article History
Received: 10 October 2025
Accepted: 28 January 2026
First Online: 10 February 2026
Competing interests
: The A.G.-S. laboratory has received research support from Avimex, Dynavax, Pharmamar, 7Hills Pharma, ImmunityBio and Accurius, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer, Virofend and Prosetta, outside of the reported work. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott, Astrazeneca and Novavax. A.G.-S. is an inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work. The other authors declare no conflict of interest.
